Biomed Faculty Directory

Office of the Dean Administration Departments Research Alpert Medical School Giving

Susan Cu-Uvin, MD

Edit My Page
Susan Cu-Uvin

Title: Professor of Obstetrics & Gynecology and Professor of Medicine and Professor of Health Services, Policy & Practice
Department: Obstetrics & Gynecology

+1 401 793 4775, +1 401 793 4775

Download Susan Cu-Uvin's Curriculum Vitae in PDF Format

Overview | Research | Grants/Awards | Teaching | Publications

Dr. Cu-Uvin's research focuses on Human Immunideficiency Virus (HIV) in women primarily in understanding the effect of antiretroviral therapy on HIV shedding in the female genital tract. She is also involved in research on Sexually Transmitted Diseases (STDs): human papilloma virus (HPV, genital warts) in the cervix and anal canal of HIV infected women, cervical/anal dysplasia or cancer, HPV vaccines, herpes and bacterial vaginosis. She collaborates on studies of microbicides to prevent HIV transmission.


Dr. Susan Cu-Uvin is an Professor of Obstetrics and Gynecology and Medicine at Brown University. She is the Director of the Immunology Center at the Miriam Hospital, Brown University, a clinic that serves almost 1,200 HIV infected patients. She is also the director of the Women and AIDS Core, for the Center for AIDS Research (CFAR) at Brown University. She is director of the Research program of the Brown/ Women and Infants Hospital Center of Excellence in Women's Health. She devotes 100% of her time to HIV related care and clinical research. She was the Chair of the Women's Health Committee of the Adult AIDS Clinical Trials Group (AACTG) from 2004-2006. She is the Principal Investigator of an RO1 to assess antiviral therapy and HIV in the female genital tract (AI40350), an co-PI of an RO3 to assess HIV-1 genital tract shedding among Cambodian women (TW6981), and a World AIDS Foundation grant to establish a HIV women's clinic in Cambodia and provide training to Cambodian health care professionals for research readiness for future projects related to HIV in women. She is a co-investigator of the CDC funded study to understand the natural history of HIV and AIDS in the era of highly active antiretroviral therapy (SUN).She served on the Institute of Medicine's Committee on Perinatal Transmission of HIV to investigate interventions to decrease vertical transmission of HIV within the United States. She chaired the NIH advisory committee on HIV related research in women and girls in 2008 and is a member of the NIH advisory committee on HIV related research in microbicides. She is also a member of the Global Microbicide Project scientific advisory group. She is a member of the Fogarty Executive Committee at Brown University and has been a very active mentor for international trainees in HIV/AIDS care and research.



Research Description

Antiviral Therapy and Human Immunodeficiency Virus (HIV)-1 in the Genital Tract of Women

1. In the presence of antiretroviral therapy, viral replication within the female genital tract may lead to the development of drug resistant mutants that is different from blood plasma.
2. Antiretroviral drug levels in the female genital tract may often be lower than in the blood plasma. Differences in drug exposure may be associated with differences in virus replication and selection of resistant HIV-1 variants during drug failure.
3. HIV can be recovered in vitro from cells in the female genital tract during successful therapy and it may be genetically different from the HIV variants recovered from the blood cell latent reservoir.

Specific Aims:
1. To understand the relative dynamics of viral failure and viral replication in the female genital tract.
1a. To compare drug resistance mutations and other measures of genetic relatedness between HIV-1 in blood versus genital secretions.
1b. To determine whether virologic failure occurs earlier in the blood or genital tract in women who are being propectively followed during successful rescue therapy.
1c. To determine whether drug resistant mutations are acquired earlier in blood or genital tract.
1d. To determine whether different genital tract subcompartments (endocervix, ectocervix, vagina) differ in viral load response to rescue therapy or in genetic changes in HIV-1 pol, including resistance mutations.
2. To assess drug exposure and patterns of drug resistance in the female genital tract.
2a. To characterize drug exposure in the genital tract as well as in blood.
2b. To determine whether differences in blood and genital tract drug exposure are associated with differences in drug resistance mutations.
2c. To determine whether differences in blood and genital tract drug exposure are associated with differences in viral load.
3. To evaluate cellular reservoirs of HIV in the female genital tract.
3a. To determine whether viral load in the genital tract is intermittently detectable during effective Highly Active AntiRetroviral Therapy (HAART) and to examine whether this coincides with transiently detectable viral load ("blips") in the blood compartment.
3b. To determine whether viruses can be recovered in vitro from cells in genital tract when cell-free genital tract and blood viral load are undetectable.
3c. To compare the sequence relatedness of cell-associated virus recovered from female genital tract to that of virus recovered from blood cells.

HIV-1 Genital Tract Shedding and Asymptomatic HSV-2 Infection Among HIV-Seropositive Women on Highly Active Antiretroviral Therapy

Asymptomatic genital HSV-2 shedding will increase HIV-1 in the genital tract of HIV-infected women on HAART.

Chronic suppression of asymptomatic HSV-2 with acyclovir will reduce the presence and/or the quantity of HIV-1 RNA shedding from the female genital tract among women on HAART.

Primary Specific Aim 1:
To measure the presence and quantity of HIV-1 RNA genital tract shedding among asymptomatic HSV-2 seropositive women on HAART who are receiving acyclovir for chronic HSV-2 suppression compared to similar women not receiving acyclovir.

Secondary Specific Aim 2:
To correlate the quantity of HIV-1 RNA with the quantity of HSV-2 DNA in women shedding both viruses simultaneously.


2003 Bruce M. Selya Annual Award for Research Excellence, Lifespan, Brown University

2004 Global Alliance for the Immunization Against AIDS (GAIA) Foundation and City of Providence, Hope is a Vaccine Award

2005 The Rhode Island Community Planning Group for HIV Prevention, The HIV Prevention Unsung Hero Award

2005 Contance B. Wofsy Women's Health Investigator Award, The AIDS Clinical Trials Group

2006 The First Annual Health Breakthrough Awards, Ladies Home Journal


Infectious Disease Society of America, Fellow

Infectious Disease Society of Obstetrics and Gynecology

International AIDS Society-USA

American Society for Colposcopy and Cervical Pathology

Rhode Island Medical Society

Philippine Obstetrics and Gynecology Society, Fellow

Funded Research


K24 AI066884-01 (Cu-Uvin) 7/1/05-6/30/10
National Institute of Allergy and Infectious Diseases (NIAID) 50%
Mid-Career Investigator Award in Patient Oriented Research
"Antiviral Therapy and HIV in the Genital Tract of Women"
Role: Principal Investigator
Total Grant: $737,936.00

RO1AI 40350-07 (Cu-Uvin) 4/13/03-5/14/08
"Antiviral Therapy and HIV in the Genital Tract of Women"
This study will evaluate the relative dynamics of viral failure and viral replication in the female genital tract, assess drug exposure and patterns of drug resistance, and to evaluate cellular reservoirs in the female genital tract.
Role: Principal Investigator
Total Grant: $2,829,010.00

"S. japonicum and Birth Outcomes: Randomized Controlled Trial" (Freidman) 7/1/2005-6/30/2008
Role: Co-investigator

P30-AI42853 (Carpenter) 9/15/2003-9/13/2008 5%
Lifespan/Tufts/Brown Center for AIDS Research
"Women and AIDS Core": Director: Flanigan, Co-Director: Cu Uvin
This is a multi-institutional Center for AIDS Research for which three of the five broad goals are directly relevant to the current grant, i.e., 1) To stimulate translational AIDS research with women, minorities and other underrepresented groups; 2) To integrate nutritional assessment/intervention and outcomes analysis into clinical research; and 3) To encourage multidisciplinary research on the clinical issues surrounding new therapies and the accompanying extended survival of HIV-seropositive patients.
Role: Co-investigator, Co-director: HIV and Women's Core
Total Grant: $7,600,000

AI-987-013 (Flanigan) 01/01/2000-12/31/2005
National Institutes of Health (NIH) 5%
"Adult Therapeutic Clinical Trials Program for HIV/AIDS"
This project will undertake clinical trials of investigational antiretroviral drugs and treatment strategies, with emphasis on study of women and of HIV-1 replication / drug resistance in drug sanctuaries (genital tract, Central Nervous System {CNS}).
Role: Co-investigator, Chair: Women's Health Committee
Total Grant: $6,710,000

"The SUN Study" (Carpenter) 10/1/2002-6/30/2007
Centers for Disease Control
The major goals of this project are to study the many manifestations, morbidities, and moralities of Human Immunodeficiency Virus (HIV) in women in the post Highly Active Antiretroviral Therapy (HAART) era (since 1996) and to incorporate HIV prevention activities into HIV medical care.
Role: Co-investigator
Total Grant: $2,124,110.00

Brown University/Women and Infants Hospital 10/1/2004-9/30/2008
Center of Excellence in Women's Health (Phipps)
Women and Infants Hospital/Department of Health and Human Services (DHHS)

The aim of this grant is to establish and center of excellence in women's care and research at Brown University.
Role: Director, Research Component


R03 TW6981-01 (Cu-Uvin) 4/1/2004-6/30/2005
Fogarty International Research Collaborative Awards (FIRCA)/NIH
"Genital Tract HIV Shedding in Cambodian Women"
The objectives are to determine the effect of generic antiretroviral medicines on genital tract HIV subtype E shedding and to determine factors associated with genital tract HIV-a shedding in Cambodian women.
Role: Principal Investigator
Total Grant: $121,382.00

World AIDS Foundation (Cu-Uvin) 9/31/2003-5/31/2005
"Establishing a Women's Clinic in Cambodia"
The aim of this grant is to establish a center for care for HIV-infected Cambodia women and to provide training to Cambodian health care professionals on the comprehensive care of HIV-infected women, to improve research readiness for future projects related to HIV in women.
Role: Principal Investigator
Total Grant: $105,000.00

NIH (Mayer) 7/1/2000-6/30/2005
Subcontract with Fenway
Prevention Trials Network (PTN)
The PTN is established to evaluate HIV prevention interventions among different high risk
populations. Studies include evaluation of microbicides to prevent sexual transmission of HIV.
Role: Co-investigator
Total Grant: $2,036,315.00

5H4A-HA00013 (Mayer) 7/1/2003-6/30/2005
New England AIDS Education and Training Center (NEATC)
The objective of this program is to develop and coordinate education programs on HIV/AIDS infection for health care providers, residents, and students, in collaboration with the NEATC.
Role: Course Director

1 RO1 MH64455 (Morrow) 9/1/2001-8/31/2004
"A Contextual Model of Microbicide Acceptability"
The goal of this project is to develop an instrument to be used for assessing the acceptability of microbicides.
Role: Co-investigator
Total Grant: $1,125,000.00

1 R21 AI48133-01 (Kozlowski) 9/1/2000 –8/30/2003
"E. Coli LT as a Rectal and Vaginal Mucosal Adjuvant"
The major goals of this project are 1) to evaluate the safety and establish doses of LT that can be administered in the rectum and vagina of women, and 2) to test the adjuvanticity of LT at these sites by evaluating immune responses induced in groups of women who receive rectal and vaginal immunizations with antigen or antigen plus LT.
Role: Co-investigator

RO1 AI40350 (Supplement) ( Cu-Uvin) 4/1/1999-3/31/2000
National Institute on Drug Abuse (NIDA)
"Effect of Directly Observed Antiretroviral Therapy on Plasma and Cervicovaginal HIV-1 RNA Levels Among HIV-Infected Substance Abusing Women": Principal Investigator
The aim of the project was to determine the feasibility of using DOT among substance abusing women to decrease plasma and genital tract viral load.
Role: Principal Investigator

U64/CCU106795 (Carpenter) 10/01/1991 – 9/29/00
Centers for Disease Control and Prevention
"HIV Epidemiology Research Study (HERS)"
The HERS was a longitudinal study to determine the natural history of HIV infection among U.S. women.
Role: Co-investigator

HERS Substudy (Cu-Uvin) 4/1/1998–12/31/2000
Centers for Disease Control (CDC)
"Peripheral and Mucosal Immune Reconstitution after Highly Active Antiretroviral Therapy in HIV-Positive Women"
The substudy was to assess mucosal immune reconstitution among women starting highly active antiretroviral therapy.
Role: Principal Investigator

RO1 HD33215 (Mayer) 5/1/1995-4/30/1998
National Institute of Child Health and Human Development (NICHD)
"Cervicovaginal Inflammation and Infection and HIV Load"
The aim of the study was to assess the effect of cervicovaginal inflammation on HIV shedding in the female genital tract.
Role: Co-investigator

RO1 A135543 (Flanigan) 11/1/1993-10/31/1997
"Induction of Anti-HIV Ig A in Rectum and Cervix of Women"
The study evaluated the induction of immune responses in the rectum and vagina using cholera toxin.
Role: Co-investigator

NO1-HD-3-3162 3/1/1997-2/28/1998
"The Influence of Ovulatory Phase on the Detection of Human Immunodeficiency Virus Type 1 (HIV-1) in Vaginocervical Secretions from HIV-Seropositive Women": Women's Health Study (WHS) 001
The study evaluated the effect of the menstrual cycle on HIV shedding in the genital tract.
Role: Principal Investigator

Teaching Experience


1996- Fogarty HIV/AIDS Fellowship Faculty Mentor

1997- Speaker, Annual Brown University AIDS Program Forum

2000- Lecturer, BC 107, Burden of Disease in the Developing World

2002- Lecturer, Biomed 282, Pathophysiology, Infectious Diseases

2003- Preceptor, Brown Medical School and Lifespan Academic Medical Center, Internal Medicine Community Based Teaching Program

2003- Course Director, Brown University AIDS Program and New England
AIDS Training Center, Annual HIV in Women Symposium


1996-present Immunology Center Attending, The Miriam Hospital, Providence, RI, 3-4 clinic sessions per week

1996-present Inpatient and On-call Rounding, The Miriam Hospital, Providence, RI, one week per month

1996-present Preceptor, Brown Medical School students, The Immunology Center, The Miriam Hospital, Providence, RI

2000- present Lecturer, Brown University Infectious Disease Fellowship

2004-present Lecturer, Core Curriculum, Department of Obstetrics and Gynecology, Women and Infants Hospital, Providence, RI


1996- Preceptor, Brown University Undergraduate Independent Study Projects

1997- Mentor, Summer Research Asssistantships, Undergraduate and Medical Students

2000- Mentor, Summer Undergraduate Teaching and Research Assistantship (UTRA)

2000- Thesis Adviser, Undergraduate students, Brown University

2005- Mentor, Research Supplement for Underrepresented Minorities

2005- Thesis Adviser, MPH candidate, Brown University

2005- Mentor, The Women and Infants /Brown National Center of Excellence in Women's Health

1996- present

Dr. Nymia Simbulan, Professor of Sociology, University of the Philippines
Dr. Guadalupe Natividad-Villanueva, Asst. Professor, Dept. of OB-GYN, University of the Philppines
Dr. Katherine Juliano Remollino, Asst. Professor, Dept. of OB-GYN, University of the Philippines
Dr. Maria Conception Manalo, Asst. Professor, Dept. Of Pediatrics, University of the Philippines
Dr. Dorothy Agdamag, Director, Microbiology and STD Research Laboratory, San Lazaro Hospital, Manila, Philippines
Dr. Josefina Tayag, Professor of Sociology, University of the Philippines
Dr. Reynaldo Imperial, Professor of Sociology, University of the Philippines

Dr. Purnima Madhivanan, YRG Care, Chennai, India, PhD student, Univ. of California, Berkely
Dr. Sheila Shyramprasad, Director, Dept. of OB-GYN, C.S.Rainy Hospital, Chennai, India
Dr. Jessie Lionel, Associate Professor, OB-GYN, Christian Medical College, Vellore, India
Dr. Nomita Chandiok, OB-GYN, Microbicide Project, Indian Council of Medical Research

Dr. Sok Pheng, Director, Sihanoukville Hospital, Cambodia
Dr. Theng Theany, Chief of OB-GYN, Sihanoukville Hospital, Cambodia
Dr. Lim Kruy, Director, Women's HIV Clinic, Center of Hope, Phnom Penh, Cambodia

Dr. Ana Lucia Ribeiro de Vasconcelos, Ministry of Health, National Program for HIV/AIDS
Dr. Angela Andrade, Dept. Of OB-GYN, Fio Cruz Hospital, Rio de Janeiro, Brazil


Selected Publications

  • 2. Cu-Uvin, Bardeguez A, Chibwesha A. Vertical Transmission of HIV and Therapeutic Interventions . NRTI and NNRTI in AIDS Therapy. Edited by Skowron G, 2006.(IN PRESS)
  • 5. Cu-Uvin S, Bardeguez A, Chibwesha C. "Vertical Transmission of HIV and Therapeutic Interventions (NRTIs and NNRTIs). In Reverse Transcriptase Inhibitors in HIV/AIDS Therapy. Humana Press. Eds. Gail Skowron, M.D. and Richard Ogden, PhD, 2006, 425-470.(2006)
  • 4. Powrie R, Cu-Uvin S. HIV Infection in Special Populations: HIV Infection in Women. HIV, American College of Physicians. Edited by Libman H. 3rd edition, 2006.(2006)
  • 62. Cu-Uvin S. Effect of the menstrual cycle on virological parameters. J Acquir immune Def Syndr 38 : S33-34, March 2005.(2005)
  • 57. Viscidi RP, Snyder B, Cu-Uvin S, Hogan J, Clayman B, Klein S, Sobel J, Shah KV. Human Papillomavirus (HPV) Capsid Antibody Response to Natural Infection and Risk of Subsequent HPV Infection in Human Immunodeficiency Virus-Positive and -Negative Women. Cancer Epid, Biomarkers, Prevention 14(1):283-8, Jan. 2005.(2005)
  • 61. Newstein M. Losikoff P. Caliendo A. Ingersoll J. Kurpewski J. Hanley D. Cerezo J. Ramratnam B. Cu-Uvin S. Prevalence and persistence of nonnucleoside reverse transcriptase inhibitor mutations in the female genital tract. Journal of Acquir Immune Defic Syndr. 38(3):364-6, 2005 Mar 1.(2005)
  • 63. Morris AB, Dobles AR, Cu-Uvin S, Zorilla C, Anderson J, Harwell J, Keller J, Garb J. Protease inhibitor use in 233 pregnancies. J Acquir Immune Defic Syndr 40(1) : 30-33, Sept. 2005.(2005)
  • 11. Harwell J, Cu-Uvin S. Measuring HIV in the female genital tract and how this affects sexual and reproductive choices. Harvard Health Policy Review 6:57-66, Spring 2005.(2005)
  • 60. Tohill B, Heilig C, Klein R, Rompalo A, Cu-Uvin S, Brown W, Duerr A. Vaginal flora morphotypic profiles and assessment of bacterial vaginosis in women at risk for HIV infection. Infect Dis Obstet Gynecol 12 :121-126, 2004.(2004)
  • 58. Quayle AJ, Shah M, Cu-Uvin S, Politch JA, Chou C, Anderson DJ, Tuomala R, Crowley-Nowick PA, Duerr A. Implications of blood contamination for assessment of local cellular immunity in the endocervix. AIDS Res Hum Retroviruses 20(5):543-6, 2004.(2004)
  • 56. Remollino C, Brown H, Adelson-Mitty J, Clarke J, Spaulding A, Boardman L, Flanigan TP, Cu-Uvin S. Lower genital tract infections among HIV-seropositive and HIV-seronegative incarcerated women: a mandate for screening and treatment in prisons. J Correctional Health Care 10:527-42, 2004.(2004)
  • 55. Theng T, Phan S, Pugatch D, Harwell J, Rufner KM, Chhi Mean V, Mayer KH, Cu-Uvin S. HIV-1 cord-blood seroprevalence of parturient women in Sihanoukville, Cambodia. International J of STD & AIDS 15:419-421, 2004.(2004)
  • 54. Paramsothy P, Duerr A, Heilig C, Cu-Uvin S, Anderson J, Schuman P, Klein R for the HER Study Group. Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy. JAIDS 35:484-491, 2004.(2004)
  • 59. Min SS, Corbett AH, Rezk N, Cu-Uvin S, Fiscus SA, Petch L, Cohen MS, Kashuba AD. Protease Inhibitor and Nonnucleoside Reverse Transcriptase Inhibitor Concentrations in the Genital Tract of HIV-1-Infected Women. J Acquir Immune Defic Syndr. 15;37(5):1577-1580, Dec. 2004.(2004)
  • 53. Natividad-Villanueva G, Santiago E, Manalastas R, Brown HW, Ingersoll J, Caliendo AM, Mayer KH, Cu-uvin S. Human immunodeficiency virus in the plasma and cervicovaginal secretions in Filipino women. International J of STD & AIDS 14: 826-829, 2003.(2003)
  • 49. Schuman P, Ohmit S, Klein R, Duerr, Cu-Uvin S, Jamieson D, Anderson J, Shah K for the HERS. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)- seropositive and at-risk HIV-seronegative women. J Infect Dis 188:128-136, 2003.(2003)
  • 47. Harlow S, Cohen M, Ohmit S, Schuman P, Cu-Uvin S, Lin X, Greenblatt R, Gurtman A, Khalsa A, Minkoff H, Young M, Klein R. Substance use and psychotherapeutic medications: a likely contributor to menstrual disorders in HIV-seropositive women. Am J Obstet Gynecol 188:881-886, 2003.(2003)
  • 45. Duerr A, Helig CM, Miekle SF, Cu-Uvin S, Klein RS, Rompalo A, Sobel JD. HER Study Group. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women; risk factors and severity. Obstet Gynecol 101(3):548-56, 2003.(2003)
  • 44. Viscidi R, Ahdieh-Grant L, Clayman B, Fox K, Massad L, Cu-Uvin S, Shah K, Anastos K, Squires K, Duerr A, Jamieson D, Burk R, Klein R, Minkoff H, Palefsky J, Strickler H, Schuman P, Piessens E, Miotti P. Serum immunoglobluin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis 187: 194-205, 2003.(2003)
  • 46. Harwell JI, Moench T, Mayer KH, Chapman S, Rodriguez I, Cu-Uvin S. A pilot study of treatment of bacterial vaginosis with a buffering vaginal microbicide. J Women's Health 12: 255-259, 2003.(2003)
  • 48. Strickler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, Minkoff H, Duerr A, Massad LS, Celentano DD, Hall C, Fazzari M, Cu-Uvin S, Beacon M, Schuman P, Levine AM, Durante AJ, Gange S, Melnick S, Burk R. Human papillomavirus 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 95:1062-71, 2003.(2003)
  • 50. DePasquale MP, Brown AJL, Cu-Uvin S, Ingersoll J, Caliendo A, Sutton L, Donahue S, D'Aquila R. Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J Acquir Immune Defic Syndr 34:37-44,2003.(2003)
  • 52. Madhivanan P, Cu-Uvin S, Govindaraian M, Mayer K, Wilson K, Hemalatha R, Solomon S. Prevalence of cervical dysplasia among women attending HIV care in Chennai, South India. J of Obstet Gynecol of India 53: 367-370, 2003.(2003)
  • 43. Jamieson DJ, Duerr A, Burk R, Klein RS, Paramsothy P, Schuman P, Cu-Uvin S, Shah K for the HIV Epidemiology Research Study Group. Characterization of genital human papilloma virus infection in women with or at risk for HIV infection. Am J Obstet Gynecol 186:21-7, 2002.(2002)
  • 42. Wiilliams S, Flanigan TP, Cu-Uvin S, Mayer K, Williams P, Ettore CA, Artenstein AW, Duerr A, Van Cott TC. Human Immunodeficiency Virus (HIV)-specific antibody in cervicovaginal lavage specimens obtained from women infected with HIV type 1. Clin Infect Dis ;35:611-617,2002.(2002)
  • 39. Larsson M, Wilkens DT, Fonteneau JF, Beadle TJ, Merritt MJ, Kost R, Haslett PAJ, Cu-Uvin S, Bhardwaj N, Shacklett B. Amplification of low-frequency antiviral CD8+ T-cell responses using autologous dendritic cells. AIDS 16(2); 171-180, 2002 .(2002)
  • 37. Silverberg MJ, Ahdieh L, Munoz A, Anastos K, Burk R, Cu-Uvin S, Duerr A, Greenblatt R, Klein RS, Massad S, Minkoff H, Muderspach L, Palefsky J, Piessens E, Schuman P, Watts H, Shah K. The impact of HIV infection and immunodeficiency on human papilloma virus type 6 or 11 infection and on genital warts. Sexually Trans Dis 29:427-435, 2002.(2002)
  • 38. Kozlowski P, Williams SB, Lynch R, Flanigan TP, Patterson R, Cu-Uvin S, Neutra MR. Differential induction of mucosal and systemic antibody responses in women after nasal,rectal, or vaginal immunization:influence of the menstrual cycle. J of Immunol 169: 566-574, 2002.(2002)
  • 40. Jamieson DJ, Duerr A, Burk R, Klein RS, Paramsothy P, Schuman P, Cu-Uvin S, Shah K for the HIV Epidemiology Research Study Group. Characterization of genital human papilloma virus infection in women with or at risk for HIV infection. Am J Obstet Gynecol ;186:21-7,2002.(2002)
  • Prevalence, Incidence, and Persistence or Recurrence of Trichomoniasis among Human Immunodeficiency Virus (HIV)-Positive Women and among HIV-Negative Women at High Risk for HIV Infection. Clin Infect Dis. 34(10):1406-11,2002.(2002)
  • 9. Nahvi S, Flanigan TP, Cu-Uvin S. Processing of semen from human immunodeficiency virus-seropositive men for use in insemination of seronegative women. Am J Obstet Gynecol 184:1048-1049, 2001.(2001)
  • 35. Al-Harthi L, Kovacs A, Coombs R, Reichelderfer P, Wright D, Cohen M, Cohn J, Cu-Uvin S, Watts H, Lewis S, Beckner S, Landay A. A menstrual cycle pattern for cytokine levels exist in HIV-positive women: implication for HIV vaginal and plasma shedding. AIDS 15:1535-1543, 2001.(2001)
  • 34. Coombs R, Wright D, Reichelderfer P, Burns D, Cohn J, Cu-Uvin S, Baron P, Cohen M, Landay A, Lewis S. Variation of human immunodeficiency virus type 1 viral RNA levels in the female genital tract: implications for applying measurements to individual women. J Infect Dis 184:1187-91, 2001.(2001)
  • 32. Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, Duerr A, Safaeian M, Astemborski J, Daniel R, Shah K. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus-positive and HIV-negative women. J Infect Dis 184:682-90, 2001.(2001)
  • 30. Warren D, Klein RS, Sobel J, Kieke B, Brown W, Schuman P, Anderson J, Cu-Uvin S, Mayer K, Jamieson DJ, Holmberg S, Duerr A for the HIV Epidemiology Research Study Group. A multicenter study of bacterial vaginosis in women with or at risk for human immunodeficiency virus infection. Infectious Diseases in Obstetrics and Gynecology 9:133-141, 2001.(2001)
  • 28. Simbulan NP, Aguilar AS, Flanigan TP, Cu-Uvin S. High-risk behaviors and the prevalence of sexually transmitted diseases among women prisoners at the women state penitentiary in Metro Manila. Social Science and Medicine Journal 52: 599-608, 2001.(2001)
  • 29. Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, Cu-Uvin S, Bentley M, Chesney M, Rosenberg Z. The Safety and Tolerability of BufferGelTM , A Novel Vaginal Microbicide Studied in U. S. Women. Clin Infect Dis 32:476-482,2001.(2001)
  • 31. Cu-Uvin S, Hogan JW, Caliendo AM, Harwell J, Mayer KH, Carpenter CCJ for the HIV Epidemiology Research Study Group. Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. Clin Infect Dis 33:894-896, 2001.(2001)
  • 33. Jamieson DJ, Duerr A, Klein RS, Paramsothy P, Brown W, Cu-Uvin S, Rompalo A, Sobel J. Longitudinal analysis of bacterial vaginosis: findings from the HIV Epidemiology Research Study. Obstet Gynecol 98:656-63, 2001.(2001)
  • 36. Brown H, Vallabhaneni S, Solomon S, Mothis S, McGarvey S, Jackson T, Putcha M, Brenner S, Mate K, Cu-Uvin S. Attitudes towards prenatal HIV testing and treatment among pregnant women in southern India. International J of STD & AIDS 12(6):390-4, 2001.(2001)
  • 10. Nahvi, Shadi MD. Flanigan, Timothy P. MD. Cu-Uvin, Susan MD. Semen processing for HIV-discordant couples: Reply. Am J Obstet Gynecol 185(6):1433-4, 2001.(2001)
  • 3. Mileno MD and Cu-Uvin S. HIV and other Infections in Pregnancy in the Tropics. In: Contemporary Obstetrics and Gynecology for Developing Countries. Okonofua, F; Odunsi, K; Briggs ND, Otubu, JA (Eds.). West African Publishers, Lagos, Nigeria, 2000.(2000)
  • 19:187-193, 2000.(2000)
  • 25. Reichelderfer P, Coombs R, Wright D, Cohn J, Burns D, Cu-Uvin S, Baron P, Cohen M, Landay A, Beckner S, Lewis L, Kovacs A. Effect of Menstrual Cycle on Human Immunodeficiency Virus Type 1 Levels in the Peripheral Blood and Genital Tract. AIDS 14:2101-2107, 2000.(2000)
  • 24. Morris AB, Cu-Uvin S, Harwell JI, Garb J, Zorilla C, Vajaranant M, Dobles AR, Jones TB, Carlan S, Allen DY. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immun Def Syndr 25:306-311, 2000.(2000)
  • 22. Harlow S, Schuman P, Cohen M, Ohmit S, Cu-Uvin S, Lin X, et al. The Effect of Human Immunodeficiency Virus Infection on Menstrual Dysfunction. J Acquir Immun Def Syndr 24:68-75, 2000(2000)
  • 20. Al-Harthi L, Wright D, Anderson A, Cohen M, Matiyahu D, Cohn J, Cu-Uvin S, Burns D, Reichelderfer P, Lewis S, Beckner S, Kovacs A, Landay A. The impact of ovulatory cycle on cytokine production: evaluation of systemic, cervicovaginal, and salivary compartments. J Interferon and Cytokine Res 20:719-24, 2000.(2000)
  • 19. Newman S, Sarin P, Kumarasamy K, Amalraj K, Rogers M, Madhivanan P, Flanigan T, Cu-Uvin S, McGarvey S, Mayer K, Solomon S. Marriage, monogamy, and HIV: a profile of HIV-infected women in south India. International J of STD & AIDS. 11: 250-253, 2000.(2000)
  • 17. Cu-Uvin S, Caliendo A, Reinert S, Chang A, Juliano-Remollino C, Flanigan TP, Mayer KH, Carpenter CCJ. Effect of Highly Active Antiretroviral Therapy on Cervicovaginal HIV-1 RNA. AIDS 14:415-421, 2000.(2000)
  • 18. Farley JL, Mitty J, Lally M, Burzynski J, Tashima K, Rich J, Cu-Uvin S, Spaulding A, Normandie L. Snead M, Flanigan TP. Comprehensive Medical care Among HIV-Positive Incarcerated Women: The Rhode Island Experience. J Women's Health 9:51-56, 2000.(2000)
  • Flanigan TP, Carpenter CCJ, Nixon DF (2000), Quantification of HIV-1-specific(2000)
  • 23. Cu-Uvin S, Wright DJ, Anderson D, Kovacs A, Watts H, Cohn J, Landay A, Reichelderfer P. Hormonal Levels Among HIV-1-Seropositive Women Compared to High-Risk HIV-Seronegative Women During the Menstrual Cycle. J Women's Health 9:857-863,2000.(2000)
  • 26. Kozlowski PA, Lynch RM, Patterson RR, Cu-Uvin S, Flanigan TP, Neutra MR. Modified wick method using weck-cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. JAIDS 24:297-309, 2000.(2000)
  • 1. Committee on Perinatal Transmission of HIV, Institute of Medicine. Reducing the Odds: Preventing Perinatal Transmission of HIV in the United States. Edited by Stoto MA, Almario DA, McCormick MC. Washington, DC. National Academy Press; 1999.(1999)
  • 7. Cu-Uvin S. Antiretroviral Treatment During Pregnancy. Improving the Management of HIV Disease (IAS-USA) 7:14-18, 1999.(1999)
  • 16. McCormick Mc, Davidson EC, Stoto MA for the Committee on Perinatal Transmission of HIV. Preventing Perinatal Transmission of Human Immunodeficiency Virus in the United States. Obstet Gynecol 94:795-8,1999.(1999)
  • 15. Cu Uvin S, Hogan J, Warren D, Klein RS, Peipert J, Schuman P, Holmberg S, Anderson J, Schoenbaum E, Vlahov D, Mayer KH. Prevalence of Lower Genital Tract Infections Among HIV-Seropositive and HIV-Seronegative Women. Clin Infect Dis 29:1145-50,1999.(1999)
  • 14. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Mucosal Vaccination Strategies for Women. J Infect Dis 179 (Suppl 3):S493-S498, 1999.(1999)
  • 6. Star J, Powrie R, Cu-Uvin S, Carpenter CCJ. Should women with human immunodeficiency virus be delivered by cesarean? Obstet Gynecol 94:799-801, 1999.(1999)
  • 8. IAS Position Paper on Prevention of HIV-1 Mother-to-Child Transmission. International AIDS Society, 1-7, July,1999.(1999)
  • 13. Cu Uvin S, Caliendo AM, Reinert SE, Mayer KH, Flanigan TP, Carpenter CCJ. HIV-1 in the Female Genital Tract and the Effect of Antiretroviral Therapy. AIDS 12:826-7, 1998.(1998)
  • 12. Farrar D, Aromin I, Cu Uvin S, Mileno M. Hypospadias Associated with the Use of High Dose Megestrol Acetate in an HIV Infected Woman. Genitourinary Med 73:226, 1997.(1997)
  • 11. Ruiz R, Cu Uvin, S, Fiore T, Flanigan TP. Toxoplasmosis in HIV-positive Women: Seroprevalence and the Role of Prophylaxis in Preventing Disease. AIDS 11:119, 1997.(1997)
  • 10. Cu Uvin S, Parekh B, Anderson D. Human Immunodeficiency Virus-1 Shedding in the Genital Tract of a Female Long-term Nonprogressor Without Detectable Plasma Human Immunodeficiency Virus Ribonucleic Acid. Am J Obstet Gynecol, 177:490-91, 1997.(1997)
  • 9. Cu Uvin S, and Caliendo AM. Cervicovaginal Human Immunodeficiency Virus Secretion and Plasma Viral Load in Human Immunodeficiency Virus-Seropositive Women. Obstet & Gynecol 90:739-743, 1997.(1997)
  • 7. Kozlowski PA, Cu Uvin S, Neutra MR, Flanigan TP. Comparison of the Oral, Rectal, and Vaginal Immunization Routes for Induction of Antibodies in Rectal and Genital Tract Secretions of Women. Infect & Immun 65:1387-94, 1997.(1997)
  • 6. Farrar DJ, Cu Uvin S, Caliendo A, Costello S, Murphy DM, Flanigan TP, Mayer KH, Carpenter CCJ. Detection of HIV-1 RNA in Vaginal Secretions of HIV-Seropositive Women Who Have Undergone Hysterectomy. AIDS 11:1296-7, 1997.(1997)
  • 8. Quesnel A, Cu Uvin S, Murphy D, Ashley RL, Flanigan T, Neutra MR. Comparative Analysis of Methods for Collection and Measurement of Immunoglobulins in Cervical and Vaginal Secretions of Women. J Immun Methods 202:153-161, 1997.(1997)
  • 5. Cu Uvin S, Flanigan TP. Human Immunodeficiency Virus Infection and Sexually Transmitted Diseases. Medicine and Health Rhode Island 80:335-38, 1997.(1997)
  • 4. Flanigan TP, Cu Uvin S, Rich JD, Mileno MD, Vigilante K, Tashima K. Update of HIV and AIDS in North America. Medicine and Health, Rhode Island 79:180-187, 1996.(1996)
  • 5. Cu Uvin S, Flanagan K, Culff K, et al. Cervical Dysplasia and HIV in Women Inmates. J Women's Health 5:603-608, 1996.(1996)
  • 4. Cu Uvin S, Flanigan TP, Rich JD, Mileno MD, Mayer KH, Carpenter CCJ. HIV and AIDS Among North American Women. Am J Med 101:316-322, 1996.(1996)
  • 3. Boardman LA, Peipert, JF, Cooper A, Cu Uvin S, Flanigan TP, Raphael SI. Cytologic/Histologic Discrepancy in HIV-Positive Women Referred to a Colposcopy Clinic. Obstet & Gynecol 84:1016-20, 1994.(1994)
  • 2. Cu Uvin S, McLean C, Flanigan TP, Fiore T, Jesdale B, Peipert J, Carpenter CCJ. Cervical Cytologic Abnormalities in HIV Seropositive Women: Cytologic and Histologic Correlation. J Womens Health 3:179-184, 1994.(1994)
  • 2. Cu-Uvin, S, Flanigan TP, Carpenter CCJ. Routine Gynecologic Monitoring of HIV seropositive Women: Research and Recommendations. AIDS Reader 3:133-40, 1993.(1993)
  • 1. Flanigan TP, Cu-Uvin, S, Fiore T, Vigilante K, Kizirian J, Carpenter CCJ. HIV Infection in Rhode Island Women. Rhode Island Medicine 76:463-466, 1993.(1993)
  • 3. Flanigan TP, Cu-Uvin S, Carpenter CCJ, Vigilante K. Spectrum of Clinical Illness among Women Infected with the Human Immunodeficiency Virus. Opportunistic Complications of HIV 2:15-22, 1993.(1993)
  • 51. Harwell J, Flanigan TP, Mitty J, Macalino G, Caliendo A, Ingersoll J, Stenzel M, Carpenter CCJ, Cu-Uvin S. Directly observed antiretroviral therapy to reduce genital tract and plasma HIV-1 RNA in women with poor adherence. AIDS 17:1990-1993, 2003.(1990)
  • 1. Cu S., Abalos J, Puertollano, et al. Existence of Kidney Disease in Pregnant Hypertensives. Philippine Journal of Obstetrics and Gynecology April-June, 59-74, 1988.(1988)
  • T-cell responses at the mucosal cervicovaginal surface. AIDS 14:1911-1915, 2000.(1911)
  • 64. Koshiol JE, Schneider JC, Jamieson D, Marshall S, Duerr A, Heilig C, Shah K, Klein R, Cu-Uvin S, Schuman P, Celentano D, Smith J. Time to clearance of Human Pappiloma Virus (HPV) by type and Human Immunodeficiency Virus (HIV) status. International J of Cancer ( in press).
  • 41. Cu-Uvin S, Ko H; Jamieson D; Hogan J; Schuman P; Anderson J; Klein R
  • reproducibility of human papillomavirus identification in cervical specimens
  • 27. Daniel R, Ahdieh L, Hayden D, Cu-Uvin S, Shah KV. Intra-laboratory
  • 21. Shacklett BL, Cu-Uvin S, Beadle TJ, Pace CA, Fast NM, Donahue SM, Caliendo AM,
  • by a polymerase chain reaction-based assay, J of Clin Virol